Last updated: September 23, 2026
Butoconazole nitrate is a mature, prescription vaginal antifungal with limited remaining intellectual-property protection and low standalone commercial visibility. The product is marketed primarily as a generic 2% vaginal cream, while the former branded products Femstat and Gynazole-1 no longer drive a meaningful branded revenue pool. Market value is concentrated in low-cost generic supply, pharmacy distribution, and treatment demand for vulvovaginal candidiasis.
What is the current market status of butoconazole nitrate?
Butoconazole nitrate is an imidazole antifungal used for the treatment of vulvovaginal candidiasis. U.S. products are generally supplied as a 2% vaginal cream in a 5-gram applicator dose. The drug is administered intravaginally and has been available in both multi-day and single-dose formulations.
| Attribute |
Butoconazole nitrate |
| Therapeutic class |
Imidazole antifungal |
| Primary indication |
Vulvovaginal candidiasis |
| Common dosage form |
2% vaginal cream |
| Typical package |
5 grams with vaginal applicator |
| Regulatory status |
Prescription drug in the United States |
| Reference products |
Femstat, Gynazole-1 |
| Current commercial structure |
Generic-dominated |
| Biologic status |
Small-molecule drug |
| Biosimilar exposure |
None |
| Primary competitors |
Terconazole, miconazole, clotrimazole, tioconazole, fluconazole |
The principal commercial distinction is between multi-day treatment and single-dose delivery. Gynazole-1 was positioned as a single-dose product, while other butoconazole products used a three-day regimen. Treatment convenience supports differentiation, but the active ingredient itself is no longer protected by a material market-exclusivity barrier.
What patents protect butoconazole nitrate?
No material, unexpired U.S. patent estate is generally associated with the active ingredient butoconazole nitrate as a current commercial franchise. The foundational composition and product patents covering the historical branded products have expired or lost practical commercial significance.
The remaining intellectual-property position is more likely to involve:
- formulation know-how;
- manufacturing controls;
- applicator design;
- trade secrets;
- product specifications;
- regulatory dossiers; and
- contract manufacturing arrangements.
These rights can affect supply continuity, but they do not create the type of regulatory exclusivity associated with a recent small-molecule launch.
Are there active Orange Book patents for butoconazole nitrate?
The U.S. Food and Drug Administration’s Orange Book is the controlling public source for patents listed against approved drug products. Butoconazole nitrate does not have a current, high-value Orange Book patent position comparable to newer branded pharmaceuticals. The commercial market is therefore exposed primarily to abbreviated new drug application competition rather than patent litigation.
A product-specific Orange Book review should distinguish between:
- patents listed against the reference product;
- patents that have expired;
- patents with no remaining enforceable term;
- formulation or device patents that do not block all generic dosage forms; and
- regulatory exclusivity that has already lapsed.
For butoconazole nitrate, the relevant conclusion is that patent expiry has shifted competition from exclusivity management to manufacturing economics and distribution access.
When did butoconazole nitrate lose exclusivity?
Butoconazole’s original product and formulation exclusivity expired years ago. Femstat entered the market before the Hatch-Waxman generic framework became the primary commercial mechanism for later products. Gynazole-1 received FDA approval in 2003 and was a mature product by the time generic competition became established.
| Milestone |
Approximate timing |
Commercial effect |
| Original butoconazole vaginal products |
1980s |
Established the active ingredient |
| Femstat commercialization |
Late 1980s |
Created the initial branded market |
| Gynazole-1 approval |
2003 |
Added a single-dose formulation |
| Generic competition |
Mature market period |
Reduced branded pricing power |
| Current market |
2020s |
Generic and low-growth category |
The exact expiration date of any historical patent depends on the patent family, patent-term adjustment, pediatric extensions, and the specific product covered. Those historical terms do not create a current barrier to ordinary generic entry.
How many patents cover butoconazole nitrate?
The commercially relevant answer is that no meaningful set of unexpired U.S. patents protects the butoconazole nitrate market as a whole.
Historical patent families may have covered:
- the butoconazole compound;
- vaginal cream compositions;
- delivery vehicles;
- treatment methods;
- dosing schedules; and
- applicator or packaging configurations.
Expired patents can remain important for historical diligence because they explain the timing of product development and generic entry. They do not materially constrain current competition unless a narrow, separately enforceable formulation or device claim remains active.
Are there Paragraph IV challenges for butoconazole nitrate?
Butoconazole nitrate is unlikely to generate current Paragraph IV litigation of the type associated with high-value branded drugs. A Paragraph IV certification is commercially significant when a generic applicant seeks approval before listed patents expire. For a mature product with no material blocking patent estate, the principal approval route is more likely to rely on patent certifications that do not require a major challenge.
The low litigation profile reflects four factors:
- the reference product is old;
- market demand is limited;
- generic pricing is low;
- potential damages do not justify extensive patent litigation.
The absence of prominent recent Paragraph IV disputes is itself a market signal. It indicates that the relevant competitive question is not whether a generic can enter, but whether a manufacturer can profitably supply a small prescription category.
What is the FDA regulatory status of butoconazole nitrate?
Butoconazole nitrate is an FDA-approved prescription antifungal. The principal U.S. dosage form is vaginal cream, with approved products submitted through new drug applications and abbreviated new drug applications.
The regulatory burden for a new generic product is lower than for a new active ingredient, but applicants must still address:
- pharmaceutical equivalence;
- dosage-form quality;
- strength and composition;
- microbiological quality;
- container-closure performance;
- applicator compatibility;
- stability;
- labeling; and
- bioequivalence or other FDA-accepted equivalence requirements.
Vaginal creams can present more complex development issues than solid oral dosage forms. Local delivery, rheology, emulsion characteristics, preservative systems, and applicator performance can affect product comparability. These factors create technical barriers, but they are not equivalent to patent exclusivity.
What formulations are protected by butoconazole nitrate patents?
The commercially important formulations are 2% vaginal creams supplied in single-dose or multi-dose presentations. Formulation development typically addresses:
- uniform drug distribution;
- cream viscosity;
- retention at the vaginal site;
- patient-administered dosing;
- preservative performance;
- compatibility with applicator materials; and
- shelf stability.
Gynazole-1’s commercial differentiation came from a single-dose formulation and product presentation. That distinction supported convenience but did not establish durable market exclusivity after patent and regulatory protections expired.
A manufacturer seeking entry may still face formulation-development costs. The likely barrier is technical execution rather than legal exclusion. Generic applicants can compete through an equivalent cream, a different package configuration, or a clinically acceptable alternative within FDA requirements.
What patent litigation affects butoconazole nitrate?
No major current U.S. patent litigation is publicly associated with butoconazole nitrate as a commercially significant drug. Historical disputes, if any, would be less relevant to present market entry than the status of generic approvals and commercial supply.
| Litigation factor |
Current assessment |
| Active composition patent dispute |
Low |
| Active formulation patent dispute |
Low to limited |
| Paragraph IV exposure |
Low |
| ANDA litigation risk |
Low |
| Trade-secret risk |
Possible but product-specific |
| Manufacturing dispute risk |
Possible |
| Settlement-driven delayed entry |
No major current indication |
The principal legal risks are more likely to arise from manufacturing contracts, product-quality issues, trademark use, or regulatory compliance than from patent infringement.
Which companies are competing in the butoconazole nitrate market?
The market has historically included the branded sponsors of Femstat and Gynazole-1 and generic manufacturers supplying butoconazole nitrate vaginal cream. Generic availability can change by manufacturer, national drug code, wholesaler, and pharmacy channel.
The competitive set includes:
- manufacturers of generic butoconazole nitrate cream;
- suppliers of terconazole vaginal products;
- suppliers of miconazole, clotrimazole, and tioconazole;
- manufacturers of oral fluconazole; and
- pharmacies and distributors controlling generic substitution.
Company-level market share is difficult to establish because public filings generally do not report butoconazole nitrate as a separate revenue line. Generic manufacturers typically combine the product with broader women’s-health or topical-pharmaceutical portfolios.
How does butoconazole nitrate compare with competing antifungals?
Butoconazole competes on treatment duration, route of administration, tolerability, availability, and price. It does not have a strong cost advantage over all alternatives because several competing products are generic or available without a prescription.
| Product |
Active ingredient |
Typical route |
Market position |
| Butoconazole |
Butoconazole nitrate |
Vaginal cream |
Prescription generic |
| Terconazole |
Terconazole |
Vaginal cream or suppository |
Prescription generic |
| Miconazole |
Miconazole nitrate |
Vaginal cream or suppository |
Broad OTC and prescription presence |
| Clotrimazole |
Clotrimazole |
Vaginal formulation |
OTC or regional prescription use |
| Tioconazole |
Tioconazole |
Vaginal ointment |
OTC single-dose positioning |
| Fluconazole |
Fluconazole |
Oral tablet |
Systemic prescription alternative |
Butoconazole’s strongest commercial attribute is local treatment with a relatively short regimen. Its weaknesses are limited brand support, generic price competition, and substitution by better-known OTC products or oral fluconazole.
What is the revenue exposure for butoconazole nitrate?
Standalone public revenue for butoconazole nitrate is not normally disclosed by manufacturers. The drug is a low-revenue product relative to major pharmaceutical assets, and it is generally grouped within broader generic portfolios.
The financial profile is characterized by:
- low average selling prices;
- limited differentiation;
- modest unit demand;
- retailer and wholesaler purchasing power;
- possible supply interruptions from low-margin manufacturing;
- limited promotional expenditure; and
- little opportunity for premium pricing.
The historical branded franchise had greater pricing potential when Gynazole-1 was differentiated as a single-dose prescription product. That value declined as generic competition and alternative antifungal treatments expanded.
What is the likely financial trajectory?
The expected trajectory is stable-to-declining nominal revenue, with periodic volatility caused by manufacturer entry, supply exits, price changes, and channel inventory. Unit demand is linked to diagnosis rates for vulvovaginal candidiasis, prescription behavior, insurance coverage, and substitution with OTC therapies.
| Period |
Financial profile |
| Early branded period |
Higher pricing and product differentiation |
| Post-generic period |
Sharp price compression |
| Mature generic period |
Low revenue, fragmented supply |
| Forward outlook |
Flat-to-declining value unless supply concentration raises prices |
A manufacturer can still earn acceptable returns if it has efficient production, an established vaginal-product platform, or a bundled portfolio that lowers selling and regulatory costs. A standalone launch is less attractive because the addressable market is narrow and competitive pricing is difficult to sustain.
What generic launch risks exist for butoconazole nitrate?
Generic launch risk is primarily commercial and operational.
Pricing risk
Multiple suppliers can reduce reimbursement and wholesale prices quickly. A new entrant may gain volume but lose margin if incumbent manufacturers respond with aggressive pricing.
Supply risk
Vaginal creams require specialized production, filling, packaging, and applicator controls. A limited number of qualified facilities can create supply concentration. Recalls, manufacturing transfers, or shortages can affect availability.
Regulatory risk
FDA review can focus on formulation sameness, product performance, container closure, microbiological controls, and stability. A product that is chemically equivalent but operationally inconsistent may face review delays or post-approval quality problems.
Demand risk
Patients and clinicians can shift to oral fluconazole, OTC azole products, or other prescription vaginal therapies. This limits the volume available to any one generic supplier.
Are there licensing deals for butoconazole nitrate?
No major recent licensing transaction is associated with butoconazole nitrate as an independent growth asset. Historical commercialization involved rights transfers, brand ownership changes, and distribution arrangements, but these transactions have limited current strategic value compared with licensing deals involving patented drugs or biologics.
Current commercial arrangements are more likely to involve:
- contract manufacturing;
- private-label supply;
- generic product distribution;
- pharmacy wholesaling; and
- portfolio acquisitions.
The absence of large licensing activity reflects the product’s mature status, low differentiation, and limited expected return from business-development investment.
What is the biosimilar risk for butoconazole nitrate?
There is no biosimilar risk because butoconazole nitrate is a small-molecule drug, not a biologic. Competitive exposure comes from generic drugs approved through the ANDA pathway, not biosimilar products approved under the Public Health Service Act.
This distinction matters for valuation. The product does not require biologic interchangeability analysis, reference-product exclusivity management, or complex biosimilar clinical development. Its competitive environment is more price-sensitive and typically has lower barriers to entry.
How strong is the patent estate for butoconazole nitrate?
The current patent estate is weak from a commercial-protection perspective. The drug has historical formulation and product-development IP, but no widely recognized, active U.S. patent moat that supports premium pricing or delayed generic entry.
| Patent-strength factor |
Assessment |
| Active composition protection |
Weak or absent |
| Active formulation protection |
Limited |
| Method-of-use protection |
Limited practical value |
| Orange Book blocking position |
Not material |
| Manufacturing know-how |
Potentially relevant |
| Device and packaging rights |
Narrow and product-specific |
| Litigation deterrence |
Low |
| Generic substitution resistance |
Low |
The defensible assets are operational: manufacturing capability, regulatory files, customer relationships, and reliable supply.
What is the outlook for butoconazole nitrate from 2025 onward?
Butoconazole nitrate is likely to remain a low-growth, generic women’s-health product. The market should continue to exist because vulvovaginal candidiasis is common and local azole therapy remains clinically established. Revenue growth is unlikely without a new delivery system, over-the-counter switch, combination product, or meaningful geographic expansion.
Potential upside could come from:
- supply shortages affecting competing products;
- pharmacy demand for single-dose treatment;
- private-label expansion;
- new international registrations;
- contract manufacturing efficiencies; or
- a reformulated product with stronger adherence or convenience.
The larger risks are price erosion, generic substitution, declining brand recognition, and competition from non-butoconazole treatments.
Key Takeaways
- Butoconazole nitrate is a mature prescription vaginal antifungal with a generic-dominated U.S. market.
- Femstat and Gynazole-1 established the historical branded franchise, but neither provides a current high-value exclusivity platform.
- No material active patent moat is generally associated with the current market.
- Paragraph IV and patent-litigation risk are low compared with newer branded drugs.
- Formulation, applicator, manufacturing, and quality controls remain relevant technical barriers.
- Revenue is not publicly reported at the product level and is likely modest relative to major pharmaceutical products.
- The forward financial trajectory is flat to declining, with margin volatility driven by generic competition and supply concentration.
- Butoconazole has no biosimilar exposure; its competitors are conventional generic and OTC antifungals.
- Commercial value rests on efficient production, reliable supply, distribution access, and portfolio economics.
FAQs
Is butoconazole nitrate still commercially available?
Yes. Butoconazole nitrate remains available primarily as a generic 2% vaginal cream, although manufacturer and pharmacy availability can vary.
Is Gynazole-1 still a protected brand?
Gynazole-1’s historical brand and formulation protections do not create a meaningful current barrier to generic competition. The product’s single-dose positioning may remain commercially relevant, but the market is no longer protected by a strong exclusivity period.
Can butoconazole nitrate become an over-the-counter product?
An OTC switch would require FDA review of labeling, consumer self-selection, safety, and effective use without clinician supervision. No current OTC switch should be assumed without an FDA-approved regulatory action.
Does butoconazole nitrate have a market shortage risk?
Yes. Low-margin generic products can face supply risk when manufacturers exit, production is concentrated, or quality issues interrupt distribution. A shortage could increase short-term pricing but would not establish durable long-term market power.
Is butoconazole nitrate a good licensing target?
It is generally a limited licensing target unless paired with a differentiated delivery system, international expansion, private-label platform, or manufacturing advantage. The standalone active ingredient has low strategic value because its patent protection and pricing power are largely exhausted.
References
-
U.S. Food and Drug Administration. (2003). Gynazole-1 (butoconazole nitrate) vaginal cream prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products and abbreviated new drug applications. FDA.
-
DailyMed. (2024). Butoconazole nitrate vaginal cream labeling. National Library of Medicine.
